Peginterferon beta-1a

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.

In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.

• Plegridy at the U.S. National Library of Medicine Medical Subject Headings (MeSH)